Biologics, small molecules, and extraintestinal malignancies in inflammatory bowel disease: practical questions and evidence-based answers. (PubMed, Inflamm Bowel Dis) - Sep 26, 2026 - "Vedolizumab and ustekinumab show favorable safety profiles, and early data for selective anti-IL-23 agents are encouraging. Cancer treatment should not be compromised because of IBD, as chemotherapy and radiotherapy are feasible, whereas immune checkpoint inhibitors may trigger IBD flares. However, evidence remains constrained by confounding, heterogeneous populations, and limited long-term follow-up, underscoring the need for prospective safety studies."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Inflammatory Bowel Disease • Lymphoma • Melanoma • Oncology • Solid Tumor • Ulcerative Colitis • IL23A
|
|
Javier P Gisbert; María Chaparro
|